O&O Alpan was established in 2005 by Dr. Oral Alpan as a Clinical Trials center, which soon became one the most successful sites in patient recruitment. Our success led to expending our research to additional therapeutic areas such as eosinophilic esophagitis. In April 2010 Lysosomal Disorders research and treatment unit was established with the joining of Dr. Ozlem Goker-Alpan who also took the role of President and CMO of O&O Alpan. Our success over the past 5 years has rewarded us “partnership status” with CRO’s such as Quintiles, This partnership brings O&O ALPAN priority access to multiple clinical trials offering new treatment options for patients. We also offer partnership with community physicians for training and ongoing collaborative support to maximize clinical trials performance.